evaluate the efficacy and safety of DWJ211 in patient with moderate or severe submental fat
DWJ211 \_ reduction of moderate or severe submental fat
Study Type
INTERVENTIONAL
Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Enrollment
140
inject the Drug into submental fat via subcutaneous
inject the Drug into submental fat via subcutaneous
Chung-ang university hospital
Seoul, South Korea
Konkuk university medical center
Seoul, South Korea
Seoul Asan medical center
Seoul, South Korea
2-grade response : PA-SMFRS
proportion of subject who simultaneously have at least a 2 grade improvement from baseline on the PA-SMFRS at 4weeks after the last treatment
Time frame: 4 week after last treatment
2-grade response : SA-SMFRS
proportion of subject who simultaneously have at least a 2-grade improvement from baseline on the SA-SMFRS at 4weeks after the last treatment
Time frame: 4 week after last treatment
1-grade response : PA-SMFRS
proportion of subject who simultaneously have at least a 1-grade improvement from baseline on the PA-SMFRS at 4weeks after the last treatment
Time frame: 4 week after last treatment
1-grade response : SA-SMFRS
proportion of subject who simultaneously have at least a 1-grade improvement from baseline on the SA-SMFRS at 4weeks after the last treatment
Time frame: 4 week after last treatment
MRI volume response rate
change rate of reduction in SMF volume
Time frame: 4 week after last treatment
improvement: SA-SMFIS
improvement in the Subject reported submental fat impact scale overall score
Time frame: 4 week after last treatment
obtained 5 score : SSS
proportion of subjects who have more than 5 score on the SSS(somewhat satisfied)
Time frame: 4 week after last treatment
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.
thickness response rate : caliper
change rate of reduction in SMF volume
Time frame: 4 week after last treatment